Steven D. Rubin - 07 Aug 2026 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Reporting relationship: Director
Issuer ticker: ENTX
Reported as of: 07 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Aug 2026, 16:23:00 UTC
Prior SEC filing: 28 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Dana Yaacov-Garbeli, Attorney-in-fact

Key filing fact

Steven D. Rubin filed Form 4 for Entera Bio Ltd. (ENTX) on 07 Aug 2026.

Key facts

This page summarizes Steven D. Rubin's Form 4 filing for Entera Bio Ltd. (ENTX).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 07 Aug 2026, 16:23.

Change

Previous filing in this sequence was filed on 28 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001381874 Primary reporting owner

Rubin Steven D

Relationship: Director
Address: KIRYAT HADASSAH,, MINRAV BUILDING, 5TH FLOOR, JERUSALEM, ISRAEL
Signature: /s/ Dana Yaacov-Garbeli, Attorney-in-fact
Signature date: 07 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ENTX transaction

Ordinary Shares, par value NIS 0.0000769 per share

Award

Transaction value
Shares: +19,117
Change %: +127%
Price: $0.000000^*
Shares after: 34,117
Date: 07 Aug 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ENTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +33,368
Change %
Price: $0.000000^*
Shares after: 33,368
Date: 07 Aug 2026
Ownership: Direct
Underlying class: Ordinary Shares, par value NIS 0.0000769 per share
Underlying amount: 33,368
Exercise price: $1.37
Footnotes: F2

ENTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +43,405
Change %
Price: $0.000000^*
Shares after: 43,405
Date: 07 Aug 2026
Ownership: Direct
Underlying class: Ordinary Shares, par value NIS 0.0000769 per share
Underlying amount: 43,405
Exercise price: $1.37
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.

Footnote F2

Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on February 1, 2026, with one third of the options vesting on February 1, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).

Footnote F3

Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest on a quarterly basis over a one-year period that began on February 1, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan).